Global R&D Pipeline
My Favorite
Hot Targets:
Mesothelin
Back
Total number of drugs
193
Phase II and later clinical stages
3.1%
Involving companies
214
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRS-207 | CRS-207 | Live attenuated vaccine Therapeutic vaccine | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases | MSLN modulators | Johns Hopkins Bloomberg School of Public Health | Chugai Pharmaceutical Co., Ltd. Johns Hopkins Bloomberg School of Public Health CERUS CORP Aduro BioTech, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | CRS-207 | - | - | detail > | |
| Pemlimogene merolisbac | Pemlimogene merolisbac | Shared antigen vaccine Therapeutic vaccine | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | EGFRvIII antagonists MSLN inhibitors Immunostimulants | Aduro BioTech, Inc. | Aduro BioTech, Inc. Janssen Global Services LLC | Phase 2 | - | - | - | - | - | - | - | - | - | Pemlimogene merolisbac | - | - | detail > | |
| Mesothelin and Claudin 18.2 Dual-Target CAR-T(Essen Biotech) | Mesothelin and Claudin 18.2 Dual-Target CAR-T(Essen Biotech) | Autologous CAR-T | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | CLDN18.2 modulators MSLN modulators | Essen BioTech, LLC. | Essen BioTech, LLC. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | Mesothelin and Claudin 18.2 Dual-Target CAR-T(Essen Biotech) | - | - | detail > | |
| LMB-100 | LMB-100 | Fab fragment | Neoplasms | MSLN inhibitors | F. Hoffmann-La Roche Ltd. | Selecta Biosciences, Inc. F. Hoffmann-La Roche Ltd. | Phase 2 | - | - | - | - | - | - | - | - | - | LMB-100 | - | - | detail > | |
| Amatuximab | Amatuximab | Monoclonal antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | MSLN inhibitors ADCC | National Cancer Institute | National Cancer Institute | Phase 2 | - | - | - | - | Orphan Drug（European Union） | - | - | - | - | Amatuximab | - | - | detail > | |
| Misitatug blivedotin | Misitatug blivedotin | Antibody drug conjugate (ADC) | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | MSLN inhibitors Tubulin inhibitors | RemeGen Co., Ltd. | RemeGen Co., Ltd. | Phase 2 | Phase 2 | - | - | - | Fast Track（United States） Orphan Drug（United States） | - | Val-Cit-PAB-OH | MMAE | 1 - 2 | Misitatug blivedotin | - | cysteinyl | detail > | |
| Mesothelin CAR-T cell therapy(Shenzhen BinDeBio Ltd.) | Mesothelin CAR-T cell therapy(Shenzhen BinDeBio Ltd.) | Autologous CAR-T | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | MSLN inhibitors Gene transference T lymphocyte replacements | Shenzhen Binde Biotechnology Co., Ltd. | Shenzhen Binde Biotechnology Co., Ltd. Jiangsu Provincial People's Hospital | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Mesothelin CAR-T cell therapy(Shenzhen BinDeBio Ltd.) | - | - | detail > | |
| OPB-101 | OPB-101 | CAR-T | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | CD8 modulators IL-12 stimulants IL-15 modulators MSLN inhibitors | Outpace Bio, Inc. | Outpace Bio, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | OPB-101 | - | - | detail > | |
| Mesothelin targeted CAR-T cells(Fapon Biotherapy) | Mesothelin targeted CAR-T cells(Fapon Biotherapy) | CAR-T | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | MSLN modulators PD-1 inhibitors Immunologic cytotoxicity T lymphocyte replacements | Guangdong Fapon Biopharma Inc | Guangdong Fapon Biopharma Inc | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | Mesothelin targeted CAR-T cells(Fapon Biotherapy) | - | - | detail > | |
| LD-013 | LD-013 | Autologous CAR-T | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | MSLN inhibitors | Nanjing Blue Shield Biotechnology Co., Ltd. | Nanjing Blue Shield Biotechnology Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | LD-013 | - | - | detail > |
Total 193 data
1
2
3
4
5
6
...
19
20
